Amalgamated Bank Relmada Therapeutics, Inc. Transaction History

Amalgamated Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$2.24 - $4.76 $1,326 - $2,817	-592 Reduced 14.29%	3,552 $8,000
Q3 2022 Nov 09, 2022	BUY	$18.3 - $37.02 $896 - $1,813	49 Added 1.2%	4,144 $153,000
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $8,712 - $16,019	528 Added 14.8%	4,095 $78,000
Q1 2022 Jun 30, 2022	BUY	$16.72 - $26.99 $59,640 - $96,273	3,567 New	3,567 $96,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.